1[1]Doody RS,Stevens JC,Beck C,et al.Practice parameter:management of dementia (an evidence-based review).Report of the Quality Standards Subcommittee of the American Academy of Neurology[J].Neurology,2001,56:1154. 被引量：1
2[2]Wolters EC.Dopaminomimetic psychosis in Parkinson's disease patients; diagnosis and treatment[J].Neurology,1999,52 (suppl3):s10. 被引量：1
3[3]Small GW,Rabins PV,Barry PP,et al.Diagnosis and treatment of Alzheimer disease and related disorders:consensus statement of the American Association for Geriatric Psychiatry,the Alzheimer's Association,and the American Geriatrics Society[J].JAMA,1997,278:1363. 被引量：1
4[4]De Deyn PP,Rabheru K,Rasmussen A,et al.A randomized trial of risperidone,placebo,and haloperidol for behavioral symptoms of dementia[J].Neurology,1999,53:946. 被引量：1
5[5]Teri L,Logsdon RG,Peskind E,et al.Treatment of agitation in AD:a randomized,placebo-controlled clinical trial[J].Neurology,2000,55:1271. 被引量：1
6[6]Ruby CM,Kennedy DH.Psychopharmacologic medication use in nursing home care:indicators for surveyor assessment of the performance of drug regimen reviews,recommendations for monitoring,and non-pharmacologic alternatives[J].Clin Fam Pract,2001,3:577. 被引量：1
7[7]Stahl SM.Essential psychopharmacology:neuroscientific basis and practical application[M].2d ed.New York,NY:Cambridge University Press,2000. 被引量：1
9[9]Katz IR,Jeste DV,Mintzer JE,et al.Comparison of risperidone and placebo for psychosis and behavioral disturbances associ ated with dementia:a randomized,doubleblind trial[J].J Clin Psychiatry,1999,60:107. 被引量：1
10[10]Olanow CW,Watts RL,Koller WC.An algorithm(decision tree)for the management of Parkinson's disease (2001):treatment guidelines[J].Neurology,2001,56(suppl 5):S1. 被引量：1
